Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · InMed Pharmaceuticals Inc. (INM)

InMed completes 1-for-10 share consolidation and name change to Mentari Therapeutics

Neutral Impact 4 of 5 shareholder Written later

InMed Pharmaceuticals, now named Mentari Therapeutics, Inc., reported that shareholders approved all ten proposals at its November 4, 2026 meeting, including a Nasdaq share issuance tied to the pending Mentari merger. The company also completed a 1-for-10 share consolidation, cutting common shares from 5,493,735 to about 549,374, and will trade under INM from November 5, 2026. The change lowers the share count and per-share figures, and creates Series A non-voting preferred shares that carry board-election and conversion terms.

Key points

  • Shareholders approved the Nasdaq share issuance for the Mentari merger with 2,615,030 votes for, 97.295% of votes cast.
  • Common shares were consolidated from 5,493,735 to about 549,374, with trading under INM expected from November 5, 2026 under new CUSIP 457637809.
  • 4,013 preferred shares were designated as Series A Non-Voting Preferred, each convertible into 1,000 common shares, with a 19.99% ownership cap.
  • Shareholders approved redomestication from British Columbia to Nevada with 88.825% votes for; a CVR distribution record date of November 5, 2026 was set.

The filing

CompanyInMed Pharmaceuticals Inc. (INM)
Form8-K, current report
Filed with the SECNov 5, 2026, 6:04 AM ET
Accession number0001193125-26-448367

Items reported: 5.03 Bylaw / Charter Amendment5.07 Shareholder Vote Results8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.